Dose-Response Analyses Of Momelotinib (CYT387), a JAK1 and JAK2 Inhibitor, From a Phase I/II Study (CCL09101) In Treatment Of Myelofibrosis

被引：3
|
作者：
Xin, Yan
Shao, Lixin
Deng, Wei
Niforos, Demi
Kowalski, Mark
Bavisotto, Linda M.
Kawashima, Jun
Jun, Susie
Collins, Helen
Ramanathan, Srinivasan
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.1590.1590
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1590
引用
收藏
页数：2
相关论文
共 38 条
  • [31] Updated results from a randomized phase II dose-ranging study of the JAK2-selective inhibitor SAR302503 in patients with myelofibrosis (MF)
    Pardanani, Animesh Dev
    Jamieson, Catriona H. M.
    Gabrail, Nashat Y.
    Lebedinsky, Claudia
    Gao, Guozhi
    Patki, Abhay
    Liu, Feng
    Tefferi, Ayalew
    Talpaz, Moshe
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [32] Preliminary Data from the Phase I/II Study of TP-3654, a Selective Oral PIM1 Kinase Inhibitor, in Patients with Myelofibrosis Previously Treated with or Ineligible for JAK Inhibitor Therapy
    El Chaer, Firas
    McCloskey, James
    Rein, Lindsay A. M.
    Brown, Randy A.
    Green, Steven D.
    Pu, Jeffrey J.
    Shirane, Shuichi
    Shimoda, Kazuya
    Ichii, Michiko
    Yuda, Junichiro
    Scandura, Joseph
    Kabir, Sujan
    Foulks, Jason M.
    Mei, Jian
    Yang, Huyuan
    Wade, Mark
    Stapinski, Carl
    Lebedinsky, Claudia
    Rampal, Raajit K.
    BLOOD, 2022, 140
  • [33] INCB018424, an oral, selective JAK2 inhibitor, shows significant clinical activity in a phase I/II study in patients with primary myelofibrosis (PMF) and post polycythemia vera/essenlial thrombocythemia myelofibrosis (Post-PV/ET MF)
    Verstovsek, Srdan
    Kantarjian, Hagop
    Pardanani, Animesh
    Thomas, Deborah
    Cortes, Jorge
    Mesa, Ruben
    Redman, John
    Staschen, Carl-Michael
    Fridman, Jordan
    Vaddi, Kris
    Tefferi, Ayalew
    BLOOD, 2007, 110 (11) : 171A - 171A
  • [34] Safety and Efficacy of Fedratinib, an Oral, Selective JAK2 Inhibitor, in Patients with Polycythemia Vera (PV) Resistant or Intolerant to Hydroxyurea: Results from a Phase II Dose-Ranging and Dose-Expansion Study
    Pardanani, Animesh
    Harrison, Claire
    Vannucchi, Alessandro
    Shortt, Jake
    Kiladjian, Jean-Jacques
    Martinelli, Giovanni
    Rose, Shelonitda
    Zhang, Jun
    Tefferi, Ayalew
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S332 - S333
  • [35] Filgotinib (GLPG0634), an Oral JAK1 Selective Inhibitor Is Effective As Monotherapy in Patients with Active Rheumatoid Arthritis: Results from a Phase 2B Dose Ranging Study
    Kavanaugh, Arthur
    Ponce, Lucia
    Cseuz, Regina
    Reshetko, Olga
    Stanislavchuk, Mykola A.
    Greenwald, Maria
    Van der Aa, Annegret
    Vanhoutte, Frederic
    Tasset, Chantal
    Harrison, Pille
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [36] Filgotinib (GLPG0634), an Oral JAK1 Selective Inhibitor Is Effective in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis: Results from a Phase 2B Dose Ranging Study
    Westhovens, R.
    Alten, Rieke
    Pavlova, Dace
    Enriquez-Sosa, Favio
    Mazur, Minodora
    Greenwald, Maria
    Van der Aa, Annegret
    Vanhoutte, Frederic
    Tasset, Chantal
    Harrison, Pille
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [37] FILGOTINIB (GLPG0634), AN ORAL JAK1 SELECTIVE INHIBITOR IS EFFECTIVE AS MONOTHERAPY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: RESULTS FROM A 24-WEEK PHASE 2B DOSE RANGING STUDY
    Kavanaugh, A.
    Ponce, L.
    Cseuz, R.
    Reshetko, O.
    Stanislavchuk, M.
    Greenwald, M.
    Van der Aa, A.
    Vanhoutte, F.
    Tasset, C.
    Harrison, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 247 - 247
  • [38] FILGOTINIB (GLPG0634), AN ORAL JAK1 SELECTIVE INHIBITOR IS EFFECTIVE IN COMBINATION WITH METHOTREXATE IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: RESULTS FROM A 24-WEEK PHASE 2B DOSE RANGING STUDY
    Westhovens, R.
    Alten, R.
    Pavlova, D.
    Sosa, F. E. Enriquez
    Mazur, M.
    Greenwald, M.
    Van der Aa, A.
    Vanhoutte, F.
    Tasset, C.
    Harrison, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 142 - 142
1234